正在使用生物改善病情抗风湿药的类风湿关节炎患者中糖皮质激素减量与复发风险
该病例交叉研究纳入508例类风湿关节炎患者,其中267例(52.5%)至少发生一次复发并作为研究人群,分析1545次访视中记录的345次(22.3%)复发。糖皮质激素减至0 mg/天(aOR 1.45,95%CI 1.13至2.24)及减至0-2.5 mg/天(aOR 1.37,95%CI 1.06至2.01)与更高的复发风险相关;减至>2.5 mg/天未与显著升高的复发风险相关。
要点
- 糖皮质激素减至0 mg/天与复发风险升高相关(aOR 1.45,95%CI 1.13至2.24)。
- 减至0-2.5 mg/天与复发风险升高相关(aOR 1.37,95%CI 1.06至2.01)。
- 减至>2.5 mg/天未与显著升高的复发风险相关。
核心结论
- 减至>2.5 mg/天在复发风险方面总体有效。
- 糖皮质激素减至≤2.5 mg/天时复发风险更高。
- 该研究可能有助于为使用生物改善病情抗风湿药的类风湿关节炎患者设计新的减量策略。
研究设计与样本
- 采用病例交叉研究设计,评估类风湿关节炎患者复发风险更高的相关因素。
- 研究纳入508例类风湿关节炎患者,其中267例(52.5%)至少发生一次复发并作为病例交叉研究人群。
- 暴露期定义为复发前6个月,对照期为无复发访视前6个月;暴露因素为糖皮质激素减至不同剂量。
主要发现
- 共分析1545次访视,记录345次(22.3%)复发。
- 糖皮质激素减至0 mg/天与更高的复发风险相关(aOR 1.45,95%CI 1.13至2.24)。
- 糖皮质激素减至0-2.5 mg/天与更高的复发风险相关(aOR 1.37,95%CI 1.06至2.01)。
- 减至>2.5 mg/天未与显著升高的复发风险相关。
关键数值与推荐
- 糖皮质激素减至0 mg/天:aOR 1.45,95%CI 1.13至2.24。
- 糖皮质激素减至0-2.5 mg/天:aOR 1.37,95%CI 1.06至2.01。
- 糖皮质激素减至>2.5 mg/天:未与显著升高的复发风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glucocorticoids are still a mainstream of rheumatoid arthritis (RA) treatment. Reducing glucocorticoids should be attempted in all patients. However, choosing the right tapering strategy is challenging. The primary aim of our study is to determine the dose-response association between glucocorticoid tapering and risk of flare in RA. METHODS: We conducted a case-crossover study to determine the factors associated to higher risk of flare in patients with RA. In case-crossover studies time-varying factors are assessed before events (hazard periods) and before control periods. We defined hazard periods as the 6 months immediately preceding flares of RA. Control periods were the 6 months prior to visits without flare. Exposure of interest was the tapering of glucocorticoids to various doses. RESULTS: 508 patients with RA were included in the study and 267 (52.5%) had at least a flare and served as the case-crossover study population. 1545 visits were available for analysis and 345 (22.3%) flares were recorded. Discontinuation of glucocorticoids (ie, tapering to doses of 0 mg/day) and tapering to 0-2.5 mg/day was associated with higher risk of flare (adjusted OR (aOR) of 1.45, 95% CI: 1.13 to 2.24 and aOR of 1.37; 95% CI: 1.06 to 2.01, respectively). Tapering to doses >2.5 mg/day was not associated with significantly higher risk of flare. CONCLUSIONS: We found that tapering to doses of >2.5 mg/day was generally effective in terms of risk of flare. Flare risk was higher when glucocorticoids were tapered to doses ≤2.5 mg/day. Our study might help design new tapering strategies in patients with RA on biological disease-modifying antirheumatic drugs.
引用
- Adami G, Fassio A, Rossini M, et al. Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs). RMD Open. 2023. PMID: 36599630. doi:10.1136/rmdopen-2022-002792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。